Nifty
:
24231.85
Sensex
:
77537.72
153.55 (0.64%)
628.04 (0.82%)
Nifty
Sensex
:
:
24231.85
77537.72
153.55 (0.64%)
628.04 (0.82%)

Glenmark Pharmaceuticals Ltd.

Pharmaceuticals & Drugs - Global

Rating :
80/99

BSE: 532296 | NSE: GLENMARK

NSE BSE
2332.90
20-Aug-2026
  • Open
  • High
  • Low
  • Previous Close
  •  2264
  •  2342
  •  2252.1
  •  2246.50
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  552157
  •  1276707415.3
  •  2474
  •  1792.6

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 65,617.24
  • 36.50
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 64,440.98
  • 0.11%
  • 5.99

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 46.65%
  • 2.08%
  • 10.60%
  • FII
  • DII
  • Others
  • 20.89%
  • 17.82%
  • 1.96%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 6.46
  • 6.66
  • 12.86

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 8.42
  • 14.53
  • 30.78

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 2.08
  • 7.66
  • -

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 14.64
  • 13.75
  • -

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 3.07
  • 3.52
  • 4.85

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 11.26
  • 12.33
  • 16.07

Earnings Forecasts:

(Updated: 15-08-2026)
Description
2026
2027
2028
2029
Adj EPS
78
-6
29.3
57.13
P/E Ratio
29.91
-388.82
79.62
40.83
Revenue
27.96
22.99
20.09
15306.8
EBITDA
16715.1
18534.1
20613.5
2997.13
Net Income
3531
4177.38
4688.08
1719.54
ROA
2265.67
2757.26
3083.85
13.49
P/B Ratio
-1.68
-1.36
-0.67
6.24
ROE
4.85
4.06
3.34
14.67
FCFF
19.29
19.57
18.05
533.13
FCFF Yield
954.84
1333.92
2496.4
0.87
Net Debt
1.56
2.17
4.07
-632.91
BVPS
-1389.33
-1716.85
-3480.9
374.13

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Jun 26
Jun 25
Var%
Mar 26
Mar 25
Var%
Dec 25
Dec 24
Var%
Sep 25
Sep 24
Var%
Net Sales
4,018.48
3,264.44
23.10%
3,770.59
3,256.21
15.80%
3,900.62
3,387.55
15.15%
6,046.87
3,433.80
76.10%
Expenses
3,213.69
2,683.92
19.74%
3,007.99
2,695.18
11.61%
3,030.87
2,787.32
8.74%
3,687.32
2,831.88
30.21%
EBITDA
804.80
580.52
38.63%
762.60
561.03
35.93%
869.75
600.23
44.90%
2,359.55
601.91
292.01%
EBIDTM
20.03%
17.78%
20.22%
17.23%
22.30%
17.72%
39.02%
17.53%
Other Income
65.76
26.44
148.71%
189.08
11.68
1,518.84%
44.46
31.13
42.82%
200.63
39.42
408.95%
Interest
54.00
58.23
-7.26%
42.60
66.71
-36.14%
41.43
52.29
-20.77%
66.46
48.48
37.09%
Depreciation
173.17
129.93
33.28%
147.91
125.20
18.14%
154.45
122.74
25.84%
141.20
120.28
17.39%
PBT
643.39
95.58
573.14%
387.77
7.97
4,765.37%
534.00
456.33
17.02%
967.40
472.57
104.71%
Tax
160.56
48.61
230.30%
86.45
3.59
2,308.08%
130.77
108.30
20.75%
356.97
118.09
202.29%
PAT
482.83
46.97
927.95%
301.32
4.38
6,779.45%
403.23
348.03
15.86%
610.43
354.49
72.20%
PATM
12.02%
1.44%
7.99%
0.13%
10.34%
10.27%
10.10%
10.32%
EPS
17.11
1.66
930.72%
10.68
0.16
6,575.00%
14.29
12.33
15.90%
21.63
12.55
72.35%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 26
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Net Sales
17,736.56
16,982.51
13,321.74
11,813.10
11,583.24
12,304.90
10,943.93
10,640.97
9,865.47
9,074.42
9,079.41
Net Sales Growth
32.94%
27.48%
12.77%
1.98%
-5.86%
12.44%
2.85%
7.86%
8.72%
-0.05%
 
Cost Of Goods Sold
4,977.69
4,687.07
4,287.37
4,352.00
4,204.38
4,312.08
3,620.18
3,623.78
3,283.71
2,963.32
2,552.03
Gross Profit
12,758.87
12,295.44
9,034.37
7,461.10
7,378.85
7,992.82
7,323.75
7,017.18
6,581.76
6,111.10
6,527.39
GP Margin
71.94%
72.40%
67.82%
63.16%
63.70%
64.96%
66.92%
65.94%
66.72%
67.34%
71.89%
Total Expenditure
12,939.87
12,410.09
10,970.36
10,617.77
9,948.23
9,984.60
8,859.55
8,942.89
8,279.67
7,459.05
7,042.71
Power & Fuel Cost
-
134.13
131.40
124.00
111.75
200.64
164.67
173.69
165.25
137.47
127.02
% Of Sales
-
0.79%
0.99%
1.05%
0.96%
1.63%
1.50%
1.63%
1.68%
1.51%
1.40%
Employee Cost
-
3,577.85
3,022.06
2,868.14
2,600.78
2,447.42
2,343.71
2,254.78
2,056.07
1,871.84
1,640.81
% Of Sales
-
21.07%
22.69%
24.28%
22.45%
19.89%
21.42%
21.19%
20.84%
20.63%
18.07%
Manufacturing Exp.
-
763.17
767.88
1,012.86
633.51
784.63
638.74
669.50
725.16
648.59
546.75
% Of Sales
-
4.49%
5.76%
8.57%
5.47%
6.38%
5.84%
6.29%
7.35%
7.15%
6.02%
General & Admin Exp.
-
1,758.14
1,457.32
1,313.59
1,212.13
1,264.86
1,027.60
1,168.32
891.10
526.29
1,022.89
% Of Sales
-
10.35%
10.94%
11.12%
10.46%
10.28%
9.39%
10.98%
9.03%
5.80%
11.27%
Selling & Distn. Exp.
-
1,431.79
1,270.52
892.72
1,137.20
896.31
943.21
1,005.63
1,125.08
996.99
1,064.70
% Of Sales
-
8.43%
9.54%
7.56%
9.82%
7.28%
8.62%
9.45%
11.40%
10.99%
11.73%
Miscellaneous Exp.
-
57.94
33.81
54.46
48.49
78.68
121.44
47.19
33.29
314.55
1,064.70
% Of Sales
-
0.34%
0.25%
0.46%
0.42%
0.64%
1.11%
0.44%
0.34%
3.47%
0.97%
EBITDA
4,796.70
4,572.42
2,351.38
1,195.33
1,635.01
2,320.30
2,084.38
1,698.08
1,585.80
1,615.37
2,036.70
EBITDA Margin
27.04%
26.92%
17.65%
10.12%
14.12%
18.86%
19.05%
15.96%
16.07%
17.80%
22.43%
Other Income
499.93
460.62
113.72
839.99
288.90
166.67
50.22
159.60
208.14
91.40
37.37
Interest
204.49
208.72
207.06
515.97
349.04
298.10
353.11
377.32
334.58
285.57
237.32
Depreciation
616.73
573.48
486.01
581.91
569.17
486.71
443.55
417.17
325.90
301.88
264.37
PBT
2,532.56
4,250.83
1,772.03
937.45
1,005.70
1,702.16
1,337.93
1,063.20
1,133.45
1,119.33
1,572.38
Tax
734.75
622.79
352.07
1,867.35
329.40
447.60
412.39
320.11
375.64
315.46
382.68
Tax Rate
29.01%
31.38%
25.16%
5117.43%
137.34%
31.06%
29.83%
29.20%
28.88%
28.18%
25.66%
PAT
1,797.81
1,361.85
1,047.09
-1,899.00
-169.72
941.71
970.04
775.97
924.98
803.78
1,108.80
PAT before Minority Interest
1,797.91
1,361.95
1,047.14
-1,830.85
-89.56
993.65
970.09
775.97
924.99
803.87
1,108.75
Minority Interest
0.10
-0.10
-0.05
-68.15
-80.16
-51.94
-0.05
0.00
-0.01
-0.09
0.05
PAT Margin
10.14%
8.02%
7.86%
-16.08%
-1.47%
7.65%
8.86%
7.29%
9.38%
8.86%
12.21%
PAT Growth
138.48%
30.06%
-
-
-
-2.92%
25.01%
-16.11%
15.08%
-27.51%
 
EPS
63.71
48.26
37.10
-67.29
-6.01
33.37
34.37
27.50
32.78
28.48
39.29

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 26
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Shareholder's Funds
10,512.11
8,849.44
7,847.93
9,473.92
9,086.65
7,064.63
6,070.51
5,605.18
5,163.48
4,492.52
Share Capital
28.22
28.22
28.22
28.22
28.22
28.22
28.22
28.22
28.22
28.22
Total Reserves
10,449.88
8,812.16
7,801.48
9,428.09
9,042.13
7,014.78
6,028.59
5,566.35
5,124.75
4,462.86
Non-Current Liabilities
1,773.05
109.35
-357.23
2,621.45
1,269.61
2,803.62
3,033.01
2,279.94
2,824.12
3,257.81
Secured Loans
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Unsecured Loans
0.00
512.70
0.00
3,852.14
2,571.74
3,888.82
4,042.99
3,573.75
4,141.78
4,536.34
Long Term Provisions
176.61
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Current Liabilities
6,376.43
5,967.02
5,818.59
4,546.24
4,689.43
4,201.02
4,125.98
4,021.09
3,287.89
2,702.68
Trade Payables
3,743.87
3,051.20
2,535.93
2,000.43
2,288.66
2,237.77
2,125.84
2,220.75
1,869.78
1,743.22
Other Current Liabilities
1,467.94
436.17
1,517.23
1,605.31
1,446.27
885.78
1,001.63
1,013.21
690.60
509.32
Short Term Borrowings
0.00
1,681.49
833.36
350.00
370.00
513.01
442.60
303.02
295.04
187.19
Short Term Provisions
1,164.62
798.16
932.08
590.51
584.50
564.45
555.91
484.11
432.46
262.95
Total Liabilities
18,661.27
14,925.44
13,308.91
17,006.95
15,397.16
14,068.92
13,229.11
11,905.83
11,275.12
10,452.59
Net Block
5,914.54
4,486.82
4,210.16
5,421.76
5,887.25
5,128.85
5,028.56
3,670.25
3,029.55
2,755.09
Gross Block
12,071.85
10,364.92
9,619.64
10,359.59
10,213.47
8,731.58
8,269.83
6,527.27
5,367.95
4,769.92
Accumulated Depreciation
6,157.31
5,878.10
5,409.48
4,937.83
4,326.23
3,602.73
3,241.28
2,857.01
2,338.39
2,014.83
Non Current Assets
7,361.56
5,629.98
5,880.82
6,840.24
7,114.82
6,709.33
6,425.49
5,209.02
4,286.43
3,577.96
Capital Work in Progress
909.13
834.83
661.88
1,189.64
1,009.87
1,381.67
1,221.89
1,398.94
1,121.87
708.11
Non Current Investment
42.36
56.35
789.66
44.57
49.62
24.63
24.59
29.66
14.66
15.69
Long Term Loans & Adv.
492.67
242.74
211.70
180.80
161.38
146.29
123.97
94.36
119.78
98.94
Other Non Current Assets
2.86
9.23
7.42
3.46
6.70
27.89
26.49
15.80
0.56
0.13
Current Assets
11,299.71
9,295.47
7,428.08
8,423.64
8,282.35
7,359.58
6,803.62
6,696.82
6,988.69
6,874.64
Current Investments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Inventories
3,430.78
3,028.53
2,513.05
2,373.62
2,499.83
2,276.83
2,135.62
2,252.07
2,030.59
2,139.05
Sundry Debtors
4,963.35
3,341.95
1,858.41
3,665.17
3,101.14
2,572.05
2,408.96
2,194.59
2,331.81
2,404.32
Cash & Bank
1,176.26
1,705.23
1,659.46
1,160.30
1,411.52
1,139.16
1,111.24
937.76
1,234.69
1,057.66
Other Current Assets
1,729.32
144.97
178.21
316.61
1,269.87
1,371.54
1,147.78
1,312.40
1,391.61
1,273.61
Short Term Loans & Adv.
1,420.90
1,074.79
1,218.95
907.93
972.41
700.49
544.48
547.18
580.83
590.22
Net Current Assets
4,923.28
3,328.44
1,609.49
3,877.39
3,592.92
3,158.56
2,677.63
2,675.73
3,700.80
4,171.96
Total Assets
18,661.27
14,925.45
13,308.90
15,263.88
15,397.17
14,068.91
13,229.11
11,905.84
11,275.12
10,452.60

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 26
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Cash From Operating Activity
3,445.03
-827.60
-265.44
625.39
1,108.65
1,131.21
1,392.41
1,324.17
1,648.05
657.43
PBT
1,984.75
1,399.21
569.19
868.45
1,441.25
1,382.47
1,096.08
1,300.63
1,119.33
1,491.43
Adjustment
2,690.42
946.95
1,009.81
1,471.96
787.11
644.82
636.23
329.83
571.28
726.56
Changes in Working Capital
-447.12
-2,493.63
-796.95
-1,074.48
-561.26
-385.84
127.06
136.34
309.06
-861.51
Cash after chg. in Working capital
4,228.04
-147.47
782.05
1,265.93
1,667.09
1,641.45
1,859.37
1,766.81
1,999.67
1,356.48
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-783.01
-680.13
-1,047.49
-640.54
-558.44
-510.24
-466.95
-442.63
-351.61
-699.05
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-1,283.23
2.09
4,560.89
-528.49
-333.28
-675.24
-783.52
-698.99
-1,013.34
-712.35
Net Fixed Assets
-277.44
-307.30
-234.42
-220.67
-155.36
-184.89
-248.78
455.14
-362.24
-256.09
Net Investments
-7.30
-2,230.12
-2,632.08
-1,773.32
-1,569.44
-2,276.02
-1,445.18
-56.07
-1,345.98
-8.28
Others
-998.49
2,539.51
7,427.39
1,465.50
1,391.52
1,785.67
910.44
-1,098.06
694.88
-447.98
Cash from Financing Activity
-2,708.75
787.04
-3,906.13
-77.46
-520.49
-441.78
-444.66
-738.74
-468.50
543.15
Net Cash Inflow / Outflow
-546.95
-38.46
389.32
19.45
254.88
14.20
164.23
-113.56
166.21
488.24
Opening Cash & Equivalents
1,675.71
1,658.27
1,443.03
1,410.53
1,138.10
1,110.28
936.28
1,233.36
1,056.36
857.12
Closing Cash & Equivalent
1,174.71
1,675.71
1,658.27
1,443.03
1,410.53
1,138.10
1,110.28
936.28
1,233.36
1,056.36

Financial Ratios

Consolidated /

Standalone
Description
Mar 26
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Book Value (Rs.)
371.30
313.28
277.46
335.13
321.45
249.60
214.65
198.27
182.62
159.16
ROA
8.11%
7.42%
-11.86%
-0.54%
6.74%
7.11%
6.17%
7.98%
7.40%
11.33%
ROE
14.10%
12.56%
-21.18%
-0.97%
12.33%
14.81%
13.32%
17.21%
16.67%
27.31%
ROCE
20.35%
16.16%
4.88%
4.43%
14.19%
15.30%
14.04%
16.47%
14.77%
20.54%
Fixed Asset Turnover
3.09
2.87
2.77
2.74
2.94
2.97
1.44
1.66
1.80
2.03
Receivable days
43.78
33.06
36.38
43.76
37.24
36.01
78.95
83.73
94.95
97.29
Inventory Days
34.05
35.23
32.19
31.52
31.35
31.90
75.25
79.22
83.59
73.65
Payable days
264.58
237.83
190.23
186.18
191.57
219.98
98.44
97.43
96.28
101.59
Cash Conversion Cycle
-186.74
-169.54
-121.67
-110.90
-122.98
-152.06
55.77
65.53
82.26
69.35
Total Debt/Equity
0.00
0.25
0.13
0.46
0.40
0.67
0.80
0.80
0.90
1.05
Interest Cover
10.51
7.76
1.07
1.69
5.83
4.92
3.90
4.89
4.92
7.28

Annual Reports:

FY 2026
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017

News Update:


  • Glenmark Pharmaceuticals’ arm launches Calcium Gluconate Injection
    21st Aug 2026, 11:28 AM

    The Calcium Gluconate Injection, 1,000 mg/10 mL, 5,000 mg/50 mL and 10,000 mg/100 mL market achieved annual sales of around $69.9 million.

    Read More
  • Glenmark Pharma gets USFDA’s nod for Fluticasone Propionate Nasal Spray
    20th Aug 2026, 09:23 AM

    According to IQVIA sales data for the 12-month period ending June 2026, the Flonase Nasal Spray market achieved annual sales of around $295.2 million

    Read More
  • Glenmark Pharmaceuticals’ arm launches Sugammadex Injection
    29th Jul 2026, 09:05 AM

    Glenmark’s Sugammadex Injection is bioequivalent and therapeutically equivalent to the reference listed drug, BRIDION Injection, 100 mg/mL of Merck Sharp & Dohme LLC

    Read More
  • Glenmark Pharma’s arm gets USFDA’s nod to expand use of RYALTRIS Nasal Spray
    21st Jul 2026, 09:30 AM

    The approval was supported by a Phase 3, randomized, double-blind, placebo-controlled study involving 446 children aged 6 to 11 years with Seasonal Allergic Rhinitis

    Read More
  • Glenmark Pharmaceuticals’ arm launches Olanzapine for Injection
    6th Jul 2026, 09:30 AM

    The launch of Olanzapine for Injection underscores its strategic focus on growing a robust injectables portfolio and strengthening its presence within the institutional channel

    Read More
  • USFDA completes GMP inspection at Glenmark Pharmaceuticals’ Goa facility
    1st Jul 2026, 11:19 AM

    At the end of the inspection, the company was issued a Form 483 with six observations

    Read More
  • Glenmark Pharmaceuticals’ arm launches Methylene Blue Injection
    17th Jun 2026, 09:50 AM

    Methylene Blue Injection USP is bioequivalent and therapeutically equivalent to the reference listed drug, ProvayBlue Injection, 50 mg/10 mL, of Provepharm SAS

    Read More
  • Glenmark Pharmaceuticals’ arm launches Winlevi across key markets in Europe
    11th Jun 2026, 11:20 AM

    Glenmark has initiated direct launches in several European markets, including the Nordics, Central and Eastern Europe, and Spain

    Read More
  • Glenmark Pharmaceuticals’ arm launches Lacosamide Injection
    5th Jun 2026, 09:28 AM

    Glenmark’s Lacosamide Injection USP is bioequivalent and therapeutically equivalent to the reference listed drug, Vimpat Injection, 200 mg/20 mL (10 mg/mL), of UCB, Inc

    Read More
  • Glenmark Pharmaceuticals reports multi-fold jump Q4 consolidated net profit
    30th May 2026, 15:39 PM

    The total consolidated income of the company has increased by 21.17% at Rs 3,959.67 crore for Q4FY26

    Read More
  • Glenmark Pharmaceuticals’ arm launches Vancomycin Hydrochloride for Injection
    18th May 2026, 10:39 AM

    The Vancomycin Hydrochloride for Injection USP, 500 mg/vial and 1 g/vial market achieved annual sales of around $37.9 million

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.